Jump to content

RAP - RESAPP HEALTH LIMITED


ShareCafe
 Share

Recommended Posts

  • Replies 39
  • Created
  • Last Reply

Top Posters In This Topic

Top Posters In This Topic

Posted Images

  • 11 months later...
The company has received Therapeutic Goods Administration approval for its paediatric cough diagnostic. This follows CE Mark approval for both children and adults which allows the company to market the device across Europe.

 

The bigger prize, achieving US FDA approval, is expected late in 2019 or early 2020. Morgans continues to fully risk commercial outcomes until there is insight into initial reception across Europe and Australia.

 

There have also been positive results in the companyâââہ¡Ãƒâ€šÃ‚¬ÃƒÆ’¢Ã¢Ã¢â€š¬Ã…¾Ãƒâ€šÃ‚¢s sleep apnoea study, showing high rates of accuracy when compared with at-home comprehensive sleep studies.

 

Speculative Buy (Add) maintained. Target is raised to $0.32 from $0.28.

Link to comment
Share on other sites

  • 1 year later...

ha, ha, got to laugh

RAP finished down 1.8 per cent to 5.4c despite announcing a three-month pilot trial of its cough diagnostic smartphone app across the telemedicine services of a large European Union telehealth provider called Medgate.

 

It's just an unpaid trial at this stage, but Medgate provides 6,000 telehealth consults a day, and well over 25 per cent of GP appointments are for chest infection or cost-related.

 

At $5 a test, that could result in $1.65 million a year in revenue for ResApp, Morgans estimates.

 

"While these numbers assume full take-up across the MG network, we know from the Aus telehealth customers that reality takes a bit more time," Morgans wrote in a research note.

 

"What it does do is raise a flag across MG's EU competitors firstly that the technology exists, and importantly providing the external validation from one of the industry's biggest players that they see it as a value-add to their consults."

 

The announcement "isn't a home run at this stage, but adds confidence in the technology and marketability within the telehealth space," Morgans says.

 

The brokerage rates ResApp a speculative buy with a 13c price target.

....or, others that held RAP took advantage of this 'news' to find some buyers. Note the previous Morgans position, from 18 months ago : Speculative Buy (Add) maintained. Target is raised to $0.32 from $0.28.

Link to comment
Share on other sites

  • 5 months later...
  • 2 weeks later...
  • 3 weeks later...
  • 6 months later...
  • 2 months later...

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
 Share


×
×
  • Create New...